Eden C. Andrew

Jan 23, 2024 | mdpi.com | Eden C. Andrew |Jeremy Lewin |Jayesh Desai |Lisa Orme

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Aug 1, 2023 | onlinelibrary.wiley.com | David Hughes |Eden C. Andrew |Maddie Gilsenan |Cristina Mignone

Summary CD19-directed chimeric antigen receptor (CAR) T-cell therapy is an important therapy for relapsed or refractory acute lymphoblastic leukaemia, but its use carries the risk of immune effector cell-associated neurotoxicity syndrome (ICANS). In children, severe ICANS is almost universally reported in association with cytokine release syndrome and is reversible.